Matches in SemOpenAlex for { <https://semopenalex.org/work/W2525950252> ?p ?o ?g. }
Showing items 1 to 79 of
79
with 100 items per page.
- W2525950252 endingPage "4558" @default.
- W2525950252 startingPage "4558" @default.
- W2525950252 abstract "4558Background: In pts with metastatic RCC, bone mets are prognostic for poor outcomes and represent an unmet medical need. The Phase 3 METEOR trial (NCT01865747) assessed the efficacy and safety of C vs E in pts with RCC and ≥1 prior VEGFR TKI. The trial met its primary endpoint of improving progression-free survival (PFS; HR 0.58, 95% CI 0.45–0.75; P<0.001) (Choueiri NEJM 2015). As C has shown clinical activity in bone mets in prostate cancer pts (Smith JCO 33 2015 abs 139), we evaluated clinical outcomes in RCC pts with bone mets in METEOR. Methods: 658 pts were randomized (stratified by MSKCC risk group and number of prior VEGFR TKIs) 1:1 to receive C (60 mg qd) or E (10 mg qd). Clinical outcome measures included PFS, ORR, overall survival (OS), and safety. Exploratory endpoints included bone scan response (BSR) in pts with bone scan lesions at baseline (Brown Nucl Med Commun 2012 33:384), incidence of skeletal-related events (SRE), and changes in bone turnover markers. Results: 142 pts had bone mets ..." @default.
- W2525950252 created "2016-10-07" @default.
- W2525950252 creator A5012066163 @default.
- W2525950252 creator A5012316179 @default.
- W2525950252 creator A5012800133 @default.
- W2525950252 creator A5024147987 @default.
- W2525950252 creator A5024642006 @default.
- W2525950252 creator A5038900929 @default.
- W2525950252 creator A5045207535 @default.
- W2525950252 creator A5049672639 @default.
- W2525950252 creator A5052504518 @default.
- W2525950252 creator A5059063118 @default.
- W2525950252 creator A5059690857 @default.
- W2525950252 creator A5061095811 @default.
- W2525950252 creator A5063621818 @default.
- W2525950252 creator A5082009347 @default.
- W2525950252 creator A5087213703 @default.
- W2525950252 date "2016-05-20" @default.
- W2525950252 modified "2023-10-17" @default.
- W2525950252 title "Efficacy of cabozantinib (C) vs everolimus (E) in patients (pts) with advanced renal cell carcinoma (RCC) and bone metastases (mets) from the phase III METEOR study." @default.
- W2525950252 doi "https://doi.org/10.1200/jco.2016.34.15_suppl.4558" @default.
- W2525950252 hasPublicationYear "2016" @default.
- W2525950252 type Work @default.
- W2525950252 sameAs 2525950252 @default.
- W2525950252 citedByCount "5" @default.
- W2525950252 countsByYear W25259502522016 @default.
- W2525950252 countsByYear W25259502522017 @default.
- W2525950252 countsByYear W25259502522018 @default.
- W2525950252 crossrefType "journal-article" @default.
- W2525950252 hasAuthorship W2525950252A5012066163 @default.
- W2525950252 hasAuthorship W2525950252A5012316179 @default.
- W2525950252 hasAuthorship W2525950252A5012800133 @default.
- W2525950252 hasAuthorship W2525950252A5024147987 @default.
- W2525950252 hasAuthorship W2525950252A5024642006 @default.
- W2525950252 hasAuthorship W2525950252A5038900929 @default.
- W2525950252 hasAuthorship W2525950252A5045207535 @default.
- W2525950252 hasAuthorship W2525950252A5049672639 @default.
- W2525950252 hasAuthorship W2525950252A5052504518 @default.
- W2525950252 hasAuthorship W2525950252A5059063118 @default.
- W2525950252 hasAuthorship W2525950252A5059690857 @default.
- W2525950252 hasAuthorship W2525950252A5061095811 @default.
- W2525950252 hasAuthorship W2525950252A5063621818 @default.
- W2525950252 hasAuthorship W2525950252A5082009347 @default.
- W2525950252 hasAuthorship W2525950252A5087213703 @default.
- W2525950252 hasConcept C126322002 @default.
- W2525950252 hasConcept C126894567 @default.
- W2525950252 hasConcept C143998085 @default.
- W2525950252 hasConcept C2777472916 @default.
- W2525950252 hasConcept C2779699572 @default.
- W2525950252 hasConcept C2781064419 @default.
- W2525950252 hasConcept C71924100 @default.
- W2525950252 hasConceptScore W2525950252C126322002 @default.
- W2525950252 hasConceptScore W2525950252C126894567 @default.
- W2525950252 hasConceptScore W2525950252C143998085 @default.
- W2525950252 hasConceptScore W2525950252C2777472916 @default.
- W2525950252 hasConceptScore W2525950252C2779699572 @default.
- W2525950252 hasConceptScore W2525950252C2781064419 @default.
- W2525950252 hasConceptScore W2525950252C71924100 @default.
- W2525950252 hasIssue "15_suppl" @default.
- W2525950252 hasLocation W25259502521 @default.
- W2525950252 hasOpenAccess W2525950252 @default.
- W2525950252 hasPrimaryLocation W25259502521 @default.
- W2525950252 hasRelatedWork W2586782814 @default.
- W2525950252 hasRelatedWork W2588444411 @default.
- W2525950252 hasRelatedWork W2588477009 @default.
- W2525950252 hasRelatedWork W2588980997 @default.
- W2525950252 hasRelatedWork W2752195019 @default.
- W2525950252 hasRelatedWork W2764128276 @default.
- W2525950252 hasRelatedWork W2766335799 @default.
- W2525950252 hasRelatedWork W2793316388 @default.
- W2525950252 hasRelatedWork W4210504447 @default.
- W2525950252 hasRelatedWork W4248676769 @default.
- W2525950252 hasVolume "34" @default.
- W2525950252 isParatext "false" @default.
- W2525950252 isRetracted "false" @default.
- W2525950252 magId "2525950252" @default.
- W2525950252 workType "article" @default.